New Delhi: Organization of Standard Central Drugs (CDSCO) and laboratory testing of state drug testing identified 185 drug samples as “not standard quality” (NSQ) and four as “false” during routine supervision in June.
These fake drugs were reported from Bihar, one of the new Delhi and two from Telangana.
The monthly report published by CDSCO emphasizes the persistent call of India in maintaining drug integrity throughout the country. Of the 185 NSQ drugs, 55 were marked with central drug laboratories and 130 state laboratories.
The head of the government official in Delhi said that the drug department in Delhi has been sold to false anticolesterol drugs that are primarily used to prevent serious cardiovascular conditions such as heart attacks and strokes.
In its statement, the Ministry of Health of the Union stated that these drug samples have failed one or more specified quality parameters, from insufficient active substances to solving problems, weight uniformity or sterility.
The failure is specific to the tested dose and does not necessarily indicate wider concerns about other medicinal products from the same manufacturer that is available on the market.
“The investigation revealed that these false drugs were produced by unauthorized entities using legitimate companies, which emphasized the severity of counterfeit drug problems. Things are currently subject to investigation and strict measures will be taken under the relevant acts and rules,” the ministry said.
This strict identification and removal of NSQ and false drugs from the market is a regular cooperating exercise between central and state regulators.
Meanwhile, the Ministry of Health has taken several measures to fight the threat of false and non -standard drugs in India.
Within the plan, the government strengthened the regulatory framework by making appropriate changes in the 1940 drug and cosmetics law. The government introduced stricter punishments for the production of false and adulterated drugs. Some crimes were also made by learning and inability.
The government also strengthened the test infrastructure and provided the provision of suspension/cancellation of the license, which means that state regulators have the power to suspend or cancel manufacturing licenses by companies that have been found to produce NSQ drugs. There is an effort to ensure that all drug manufacturers monitor good production practice (GMP) on their units.
GMP is a system to ensure that products are constantly produced and controlled according to quality standards. It is a critical part of the quality of quality in the pharmaceutical industry. It ensures patient safety, product consistency, contamination or errors, etc.
In May, the Apex drug regulator declared 186 drugs non -standard. Two samples were reported within a month.
(Tagstotranslate) DCGI
